Skip to main content

Month: June 2020

BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases

PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, has entered into a strategic collaboration with the University of Florida to translate research in genetically driven disease towards clinical development and potential commercialization. The partnership combines University of Florida’s prowess in studying genetically driven disease, including its capabilities in gene therapy, with BridgeBio’s expertise in efficiently advancing therapeutics from the academic laboratory through preclinical studies and into human testing.BridgeBio believes that, too often, promising research in academia sits on the shelf without partners to move it forward. The company’s mission is to bring as much of that research forward as possible, by...

Continue reading

The North West Company Inc. annonce le financement de billets de premier rang

WINNIPEG, Manitoba, 18 juin 2020 (GLOBE NEWSWIRE) — The North West Company Inc. (la « Société » ou « North West ») a annoncé aujourd’hui avoir émis 70 millions USD en billets de premier rang, dont le produit sera utilisé pour réduire les montants prélevés des facilités de crédits dans les Activités canadiennes ainsi qu’à d’autres fins générales de l’entreprise. La capacité supplémentaire des facilités de crédit dans les Activités canadiennes provenant de ce nouveau financement devrait être utilisée pour rembourser les billets de premier rang de 70 millions USD lorsqu’ils arriveront à échéance le 16 juin 2021.Les nouveaux billets de premier rang ont été émis dans le cadre d’un placement privé en deux tranches ; 35 millions USD de titres de premier rang à un taux de 2,88 % qui arriveront à échéance...

Continue reading

Tallinna Sadam will hold a webinar to introduce the draft resolutions of the general meeting of shareholders

AS Tallinna Sadam invites interested parties to participate in a webinar tomorrow, 19.06.2020 at 10.00 (EET), where Chairman of the Supervisory Board Aare Tark, Chairman of the Management Board Valdo Kalm and Chairman of the Nomination Committee Veiko Tali will present the content of draft resolutions and answer questions before the voting period starts. In addition, the voting process and possibilities are clarified. The webinar will be held in Estonian.Anyone can take part in the webinar via the Port of Tallinn’s youtube channel. Questions can be asked from the speakers by sending them to the e-mail investor@ts.ee in advance at the latest by beginning of the webinar or during the webinar in writing via the slido application, the link to which can be found in the comments section of the webinar video.Voting of shareholders’...

Continue reading

Tallinna Sadam korraldab aktsionäride üldkoosoleku otsuste eelnõude tutvustamiseks veebiseminari

AS Tallinna Sadam kutsub huvilisi osalema homme, 19.06.2020 kell 10.00 (EET) toimuval veebiseminaril, kus nõukogu esimees Aare Tark, juhatuse esimees Valdo Kalm ja nimetamiskomitee esimees Veiko Tali tutvustavad enne hääletusperioodi algust aktsionäride üldkoosoleku otsuste eelnõude sisu ning vastavad küsimustele. Lisaks selgitatakse aktsionäride otsuste hääletamise protsessi ja võimalusi. Veebiseminar toimub eesti keeles.Veebiseminarist võivad Tallinna Sadama youtube’i kanali kaudu osa võtta kõik soovijad. Esinejatele saab esitada küsimusi, saates need eelnevalt e-mailile investor@ts.ee hiljemalt seminari alguseks või veebiseminari ajal kirjalikult läbi slido rakenduse, mille link on leitav veebiseminari video juures.Aktsionäride otsuste hääletamine toimub perioodil 22.06-29.06.2020, hääleõiguslike aktsionäride nimekiri fikseeritakse...

Continue reading

Orion Secures Initial $3.1M Award for U.S. Government Retrofit Project

MANITOWOC, Wis., June 18, 2020 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), which enables business to digitize and reduce carbon footprint by providing innovative LED lighting systems and turnkey project implementation including installation and commissioning of fixtures, controls and IoT systems, ongoing system maintenance and program management, today announced the receipt of an approximate $3.1 million award related to the LED lighting retrofit of a U.S. government facility.Orion will install LED lighting systems in a large government facility in Nevada. The lighting retrofit project is expected to commence in Orion’s fiscal 2021 second quarter and be completed during Orion’s fiscal 2022. Orion will replace legacy T5, T8, compact fluorescent and high-intensity discharge (HID) lighting systems...

Continue reading

Nephros Set to Join Russell Microcap® Index

SOUTH ORANGE, NJ, June 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nephros, Inc.(Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a preliminary list of additions posted June 5.Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.“Recognition from the Russell Microcap...

Continue reading

BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases

PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization to reach patients in need.“We are privileged to establish a framework for collaboration with Johns Hopkins University, an institution that has pioneered our understanding of Mendelian disease. Our hope is that this relationship will allow us to build on the significant advances being made in Johns Hopkins’ labs and support work to translate them as quickly and as safely as possible into meaningful medicines for patients in need,”...

Continue reading

Altera Infrastructure GP L.L.C. Announces a Change to its Board of Directors

PEMBROKE, Bermuda, June 18, 2020 (GLOBE NEWSWIRE) — Altera Infrastructure GP L.L.C. (ALIN GP), the general partner of Altera Infrastructure L.P. (Altera Infrastructure or the Partnership), announced the following change to its Board of Directors (the Board), which was first indicated on January 23, 2020:Kenneth Hvid, Board member and President & Chief Executive Officer of Teekay Corporation, has retired from the Board, effective June 17, 2020.“On behalf of the Board and leadership team, I want to thank Kenneth for his dedicated service, and his many contributions, during his tenure on the Board. Kenneth’s support has been invaluable during the transition to Brookfield’s ownership of the Partnership. We will miss his wise counsel, going forward,” commented Bill Utt, Chairman of the Board.About Altera InfrastructureAltera Infrastructure...

Continue reading

francesca’s® Provides Update on COVID-19 Response and Reports Select Preliminary First Quarter Fiscal Year 2020 Financial Results

Reopened 593 boutiques as of June 12, 2020First quarter 2020 net sales decreased 50% to $43.8 millionDelays filing of Quarterly Report on Form 10-QHOUSTON, June 18, 2020 (GLOBE NEWSWIRE) — Francesca’s Holdings Corporation (Nasdaq: FRAN) today provides an update on its COVID-19 response and reports select preliminary financial results for the first quarter ended May 2, 2020.  These preliminary results do not include the impact of non-cash impairment charges of long-lived assets, including the related income tax effect, which are expected to have a material impact on the Company’s reported results.Mr. Andrew Clarke, President and CEO, stated, “While we continue to navigate through this difficult period, we are highly encouraged to see bright spots in our business driven by the new strategies that we have been testing and scaling.  We...

Continue reading

Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors. Dr. Schmidt and Mr. Svennilson are widely respected executives with extensive Wall Street and financial markets experience in the biopharmaceutical industry. Mr. Svennilson was appointed to fill the vacancy created by the resignation of Larry Lasky, Ph.D., who stepped down from the board of directors and will continue supporting the company as a scientific advisor.“Eric and Peter will each strengthen our board’s financial expertise as Revolution Medicines continues maturing as a public company. In particular, Eric brings...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.